On Wednesday, Mineralys Therapeutics cleared an important performance benchmark, seeing its Relative Strength (RS) Rating jump into the 90-plus percentile with an improvement to 98, up from 85 the day before.
Looking For The Best Stocks To Buy And Watch? Start Here
IBD's proprietary rating tracks share price performance with a 1 (worst) to 99 (best) score. The grade shows how a stock's price movement over the trailing 52 weeks compares to all the other stocks in our database.
Decades of market research reveals that the top-performing stocks typically have an RS Rating of over 80 as they begin their biggest runs.
Mineralys Therapeutics is now considered extended and out of buy range after clearing a 16.90 buy point in a first-stage consolidation. See if the stock forms a new pattern or follow-on buying opportunity like a three-weeks tight or pullback to the 50-day or 10-week moving average.
Mineralys Therapeutics posted 0% EPS growth in its most recent report. Revenue increased 0%.
The company holds the No. 107 rank among its peers in the Medical-Biomed/Biotech industry group. Aurinia Pharmaceuticals, Halozyme Therapeutics and Rigel Pharmaceuticals are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Which Stocks Are Showing Improved Price Performance?
